- Home
- CLLS vs INFU Comparison
CLLS vs INFU Comparison
Compare CLLS & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- INFU
- Stock Information
- Founded
- CLLS 1999
- INFU 2005
- Country
- CLLS France
- INFU United States
- Employees
- CLLS 216
- INFU N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- INFU Medical/Dental Instruments
- Sector
- CLLS Health Care
- INFU Health Care
- Exchange
- CLLS Nasdaq
- INFU Nasdaq
- Market Cap
- CLLS 148.1M
- INFU 189.2M
- IPO Year
- CLLS 2007
- INFU N/A
- Fundamental
- Price
- CLLS $1.48
- INFU $7.98
- Analyst Decision
- CLLS Buy
- INFU
- Analyst Count
- CLLS 3
- INFU 0
- Target Price
- CLLS $7.00
- INFU N/A
- AVG Volume (30 Days)
- CLLS 235.1K
- INFU 65.5K
- Earning Date
- CLLS 11-04-2024
- INFU 03-13-2025
- Dividend Yield
- CLLS N/A
- INFU N/A
- EPS Growth
- CLLS N/A
- INFU 60.96
- EPS
- CLLS N/A
- INFU 0.07
- Revenue
- CLLS $36,042,000.00
- INFU $132,783,999.00
- Revenue This Year
- CLLS $387.77
- INFU $10.23
- Revenue Next Year
- CLLS $11.14
- INFU $8.80
- P/E Ratio
- CLLS N/A
- INFU $114.28
- Revenue Growth
- CLLS 46.96
- INFU 8.17
- 52 Week Low
- CLLS $1.41
- INFU $5.74
- 52 Week High
- CLLS $3.38
- INFU $10.03
- Technical
- Relative Strength Index (RSI)
- CLLS 38.66
- INFU 45.87
- Support Level
- CLLS $1.65
- INFU $7.42
- Resistance Level
- CLLS $2.23
- INFU $8.15
- Average True Range (ATR)
- CLLS 0.18
- INFU 0.35
- MACD
- CLLS -0.03
- INFU -0.01
- Stochastic Oscillator
- CLLS 8.54
- INFU 40.58
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.